Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan » 09:07
06/30/22
06/30
09:07
06/30/22
09:07
INBX

Inhibrx

$12.03 /

+0.59 (+5.16%)

Inhibrx completed Phase 1…

Inhibrx completed Phase 1 dose escalation of INBRX-105, a novel targeted 4-1BB agonist, in combination with Keytruda. It also reported the funding of an additional $60M from its Loan and Security Agreement with Oxford Finance to bring its cash balance to approximately $176M as of June 30. INBRX-105 is a therapeutic candidate based on the single domain antibody platform designed to agonize 4-1BB selectively in the presence of programmed death ligand 1. The study is a first-in-human, Phase 1 trial in patients with locally advanced or metastatic solid tumors. This four-part trial is designed to determine the safety profile and identify the maximum tolerated dose and the recommended Phase 2 dose of INBRX-105 administered in combination with Keytruda. Part 3, dose escalation in combination with Keytruda, has concluded with a total of 30 patients enrolled. INBRX-105 in combination with Keytruda was "reasonably" well-tolerated and durable responses in checkpoint-naive and relapsed refractory patients were observed. These results informed what Inhibrix believes to be the optimal dose level. Part 4 dose expansion cohorts will include a total of approximately 90 patients in five separate cohorts and the company expects to announce initial data from these cohorts in the first half of 2023. Inhibrx has one additional $30M tranche available under the Loan Agreement, which will be available to fund upon the initiation of a potential registration-enabling clinical trial of INBRX-101. To date, the aggregate balance of Inhibrx's outstanding term loans, which mature in January 2027, is $170.0M. The repayment schedule provides for interest-only payments until March 2025 with a potential 12-month extension.

ShowHide Related Items >><<
INBX Inhibrx
$12.03 /

+0.59 (+5.16%)

INBX Inhibrx
$12.03 /

+0.59 (+5.16%)

03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
INBX Inhibrx
$12.03 /

+0.59 (+5.16%)

Over a month ago
Hot Stocks
Inhibrx's INBRX-101 shows favorable safety profile in Phase 1 AATD trial » 09:03
05/16/22
05/16
09:03
05/16/22
09:03
INBX

Inhibrx

$16.94 /

+2.38 (+16.35%)

Inhibrx announced topline…

Inhibrx announced topline results from a Phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD. Data from this multi-country Phase 1 study are from 31 patients with AATD. Treatment was well tolerated with no severe or serious adverse events related to the study drug. Drug-related adverse events were predominantly mild and those few that were moderate in severity were all transient and reversible, with minimal or no symptomatic care. No safety-related or PK/PD-related signs of neutralizing anti-drug antibodies were observed. Dose-related increases in maximal and total INBRX-101 exposure occurred across the entirety of the single and multiple ascending dose ranges. To date, bronchoalveolar lavage fluid samples have been processed from two 80 mg/kg multiple ascending dose cohort individuals and confirm the presence of INBRX-101 in the lung fluid. Additionally, functional AAT levels were measured in plasma samples from 65 normal MM genotype individuals. This analysis revealed the 5th and 95th percentiles of functional AAT levels in the normal MM genotype individuals were 23 and 57 microM, respectively, with a median of 38 microM.

ShowHide Related Items >><<
INBX Inhibrx
$16.94 /

+2.38 (+16.35%)

INBX Inhibrx
$16.94 /

+2.38 (+16.35%)

03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
INBX Inhibrx
$16.94 /

+2.38 (+16.35%)

Earnings
Inhibrx reports Q1 EPS (80c), consensus (60c) » 16:19
05/09/22
05/09
16:19
05/09/22
16:19
INBX

Inhibrx

$14.59 /

-1.045 (-6.68%)

Reports Q1 revenue…

Reports Q1 revenue $929,000, consensus $1.1M. As of March 31 Inhibrx had cash and cash equivalents of $143.5M, compared to $131.3M as of December 31, 2021.

ShowHide Related Items >><<
INBX Inhibrx
$14.59 /

-1.045 (-6.68%)

INBX Inhibrx
$14.59 /

-1.045 (-6.68%)

03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
INBX Inhibrx
$14.59 /

-1.045 (-6.68%)

Hot Stocks
Inhibrx announces formation of Scientific Advisory Board for INBRX-101 » 09:06
04/25/22
04/25
09:06
04/25/22
09:06
INBX

Inhibrx

$16.34 /

+0.05 (+0.31%)

Inhibrx announced the…

Inhibrx announced the formation of a Scientific Advisory Board for its INBRX-101 program for the treatment of alpha-1 antitrypsin deficiency - AATD -. The SAB is comprised of global experts in AATD and will work with Inhibrx management to help guide the development of INBRX-101 to registration and beyond.

ShowHide Related Items >><<
INBX Inhibrx
$16.34 /

+0.05 (+0.31%)

INBX Inhibrx
$16.34 /

+0.05 (+0.31%)

03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
INBX Inhibrx
$16.34 /

+0.05 (+0.31%)

Over a quarter ago
Initiation
Inhibrx initiated with an Outperform at SMBC Nikko » 20:25
03/15/22
03/15
20:25
03/15/22
20:25
INBX

Inhibrx

$20.16 /

-0.045 (-0.22%)

SMBC Nikko analyst David…

SMBC Nikko analyst David Dai initiated coverage of Inhibrx with an Outperform rating and $40 price target. The company is one of the leading names at developing antibodies targeting agonist IO targets, the analyst tells investors in a research note. Dai states that given the skepticism around agonistic targets, he sees the IO programs OX40 and DR5 as currently underappreciated. The analyst further notes that the clinical data suggested that OX40 and DR5 could likely be successful in the clinic, and he expects data updates in 2022 to drive potential near-term upside.

ShowHide Related Items >><<
INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
09/21/21 JMP Securities
Inhibrx initiated with an Outperform at JMP Securities
INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

Initiation
Inhibrx initiated with an Outperform at SMBC Nikko » 17:52
03/15/22
03/15
17:52
03/15/22
17:52
INBX

Inhibrx

$20.16 /

-0.045 (-0.22%)

SMBC Nikko initiated…

SMBC Nikko initiated coverage of Inhibrx with an Outperform rating and $40 price target.

ShowHide Related Items >><<
INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
09/21/21 JMP Securities
Inhibrx initiated with an Outperform at JMP Securities
04/26/21 Credit Suisse
Inhibrx assumed with an Outperform at Credit Suisse
INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

INBX Inhibrx
$20.16 /

-0.045 (-0.22%)

Hot Stocks
Inhibrx's INBRX-101 granted FDA Orphan-Drug Designation » 09:17
03/03/22
03/03
09:17
03/03/22
09:17
INBX

Inhibrx

$21.62 /

-0.19 (-0.87%)

Inhibrx announced that…

Inhibrx announced that the FDA has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD. Alpha-1 antitrypsin deficiency, or AATD, is an inherited orphan disease affecting an estimated 100,000 patients in the United States. AATD is characterized by deficient levels of the AAT protein, which causes loss of lung tissue and function and decreased life expectancy. INBRX-101 is a recombinant human AAT-Fc fusion protein designed to achieve and maintain levels of AAT found in healthy individuals with a favorable safety profile and the potential for once-monthly dosing. Data from the first multiple ascending dose cohort of INBRX-101 at 40 mg/kg IV every three weeks showed the expected accumulation of functional AAT levels with observed trough levels exceeding the goal of the current standard augmentation therapy with plasma-derived AAT. Interim safety data from 24 patients with AATD showed no drug-related severe or serious adverse events. Drug-related adverse events were predominantly mild with a few moderate events, and all were transient and reversible. No signs of neutralizing anti-drug antibodies have been observed.

ShowHide Related Items >><<
INBX Inhibrx
$21.62 /

-0.19 (-0.87%)

INBX Inhibrx
$21.62 /

-0.19 (-0.87%)

11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
09/21/21 JMP Securities
Inhibrx initiated with an Outperform at JMP Securities
04/26/21 Credit Suisse
Inhibrx assumed with an Outperform at Credit Suisse
INBX Inhibrx
$21.62 /

-0.19 (-0.87%)

INBX Inhibrx
$21.62 /

-0.19 (-0.87%)

Hot Stocks
Inhibrx treatment of Alpha-1 Antitrypsin Deficiency granted orphan status » 14:59
03/02/22
03/02
14:59
03/02/22
14:59
INBX

Inhibrx

$21.86 /

+0.05 (+0.23%)

A treatment of Alpha-1…

A treatment of Alpha-1 Antitrypsin Deficiency being studied by Inhibrx was granted FDA orphan designation status, according to a post to the agency's website. Reference Link

ShowHide Related Items >><<
INBX Inhibrx
$21.86 /

+0.05 (+0.23%)

INBX Inhibrx
$21.86 /

+0.05 (+0.23%)

11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
09/21/21 JMP Securities
Inhibrx initiated with an Outperform at JMP Securities
04/26/21 Credit Suisse
Inhibrx assumed with an Outperform at Credit Suisse
INBX Inhibrx
$21.86 /

+0.05 (+0.23%)

INBX Inhibrx
$21.86 /

+0.05 (+0.23%)

Earnings
Inhibrx reports Q4 EPS (55c), consensus (57c) » 16:18
02/28/22
02/28
16:18
02/28/22
16:18
INBX

Inhibrx

$21.50 /

-0.51 (-2.32%)

Reports Q4 revenue…

Reports Q4 revenue $2.86M, consensus $1.71M. As of December 31, 2021, Inhibrx had cash and cash equivalents of $131.3M, compared to $128.7M as of December 31, 2020. Cash and cash equivalents totaled $152.8M as of February 21, 2022.

ShowHide Related Items >><<
INBX Inhibrx
$21.50 /

-0.51 (-2.32%)

INBX Inhibrx
$21.50 /

-0.51 (-2.32%)

11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
09/21/21 JMP Securities
Inhibrx initiated with an Outperform at JMP Securities
04/26/21 Credit Suisse
Inhibrx assumed with an Outperform at Credit Suisse
INBX Inhibrx
$21.50 /

-0.51 (-2.32%)

INBX Inhibrx
$21.50 /

-0.51 (-2.32%)

Hot Stocks
Inhibrx announces results from Part 3 of the 4-part Phase 1 trial of INBRX-106 » 16:06
01/04/22
01/04
16:06
01/04/22
16:06
INBX

Inhibrx

$39.71 /

-3.4 (-7.89%)

Inhibrx announced initial…

Inhibrx announced initial results from Part 3 of the 4-part Phase 1 trial of INBRX-106, a novel hexavalent OX40 agonist, in combination with Keytruda, in development for the treatment of patients with solid tumors. Additionally, an update on single agent data from Part 1 and Part 2 of the trial was provided. In the all-comer Part 3 of this Phase 1 trial, the dose of INBRX-106 was escalated in combination with Keytruda(R) in 21 patients with locally advanced or metastatic solid tumors. INBRX-106 in combination with Keytruda was observed to be well tolerated, with predominantly mild or moderate immune-related toxicities noted. The maximum administered dose of INBRX-106 was 0.3 mg/kg, at which dose-limiting, immune-related toxicities such as dermatitis were observed. Accordingly, 0.1 mg/kg dosed every three weeks was determined to be the maximum tolerated dose of INBRX-106 in combination with Keytruda.

ShowHide Related Items >><<
INBX Inhibrx
$39.71 /

-3.4 (-7.89%)

INBX Inhibrx
$39.71 /

-3.4 (-7.89%)

11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
09/21/21 JMP Securities
Inhibrx initiated with an Outperform at JMP Securities
04/26/21 Credit Suisse
Inhibrx assumed with an Outperform at Credit Suisse
INBX Inhibrx
$39.71 /

-3.4 (-7.89%)

INBX Inhibrx
$39.71 /

-3.4 (-7.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.